Sabinsa’s Parent Company Sami Labs Breaks Ground on $30 Million USD State-of-the-Art Production Facility in India

Sami-Sabinsa Group

"The vision of a research scientist and a passionate entrepreneur takes on social and commercial expressions." This, in short, explains the genesis and growth of Sami-Sabinsa Group.

Sami-Sabinsa Group is a research-focused multinational health science company that was founded in 1991 by the late Dr. Muhammed Majeed, an internationally renowned scientist and entrepreneur in the field of evidence-based medicine. The company is a leading manufacturer of nutraceuticals and cosmeceutical ingredients, standardized herbal extracts, enzymes, probiotics, nutricosmetics, nutritional fine chemicals, and specialty chemicals.
Read More...

Sami-Sabinsa Group hosted a ground-breaking ceremony, on January 20, 2020, for a new Active Pharmaceutical Ingredients (API) manufacturing unit at Pharma SEZ Industrial Area, Hassan, Karnataka. The latest facility, with a planned investment of $30 Million USD, is part of the group’s strategy to expand existing ingredient growth, and focus on innovative new products. This will be the company’s eighth manufacturing facility.

Shri. Prajwal Gowda, Member of Parliament (MP), Hassan, and Shri. Preetham J. Gowda, Member of the Legislative Assembly (MLA), graced the ceremony, along with the senior management team of Sami-Sabinsa Group and employees of Sami Labs.

Commenting on the occasion, Dr. Muhammed Majeed, Founder and Chairman, Sami-Sabinsa Group, said, “We have been doing business in India for nearly three decades now, and our business has grown rapidly over the years. The upcoming production facility at Hassan will not only empower us to cater to the entire global market with patented and off-patent API products but will also play a vital role in boosting the export sales of the Sami-Sabinsa Group and help in doubling the company revenue.”

The first phase covering 430,556 square feet of this world-class API manufacturing unit will have a production capacity of more than 300 tons per annum. The high quality, environmentally conscious, Zero Liquid Discharge (ZLD) facility will combine user comfort, energy efficiency, responsible water management, and biodiversity development. The facility, which will be 100% cGMP and compliant with regulatory requirements, is scheduled for commissioning by 2021 and is expected to generate employment for approximately 400 people in and around Hassan.

Sabinsa’s Parent Company Sami Labs Breaks Ground on $30 Million USD State-of-the-Art Production Facility in India Ground breaking ceremonies with Dr. Muhammed Majeed, Mr. and Mrs. Shaheen Majeed, Dr. Anju Majeed, and members of the Sami-Sabinsa Group management and staff.

What We Do

Sami-Sabinsa Group Limited (formerly Sami Labs Limited), a pioneer and global leader in health science, is a leading producer of nutraceuticals, cosmeceuticals, standardized herbal extracts, fine chemicals, specialty chemicals, probiotics, and enzymes.

The company’s corporate R&D encompasses independent research divisions, including Natural Drugs, Phytochemistry, Synthetic Chemistry, Tissue Culture, Biotechnology, Analytical R&D, Biological Research, Microbiology, and Formulation R&D. These divisions collaborate in a synergistic work model to produce products that adhere to international standards.

With the collective wisdom of over 120 research scientists, Sami-Sabinsa Group has developed standardized natural extracts that render alternative therapy to emerging nutritional and health requirements across the globe.